309
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of Serum IgG Subclass Concentrations in Myasthenia Gravis Patients

, &
Pages 570-574 | Received 27 Dec 2010, Accepted 05 Jun 2011, Published online: 19 Jul 2011
 

ABSTRACT

Myasthenia gravis (MG) is an autoimmune disease characterized by preferential production of a variety of autoantibodies. We aimed to investigate serum IgG subclass levels in MG patients. Serum IgG subclass levels from 85 MG patients were determined by the immunonephelometric assay. The median levels of IgG1, IgG2, IgG3, and IgG4 in MG patients were 7,360 mg/L, 5,750 mg/L, 860 mg/L, and 340 mg/L, respectively. When compared with normal controls, a significant increase of IgG1 (p = .000), IgG2 (p = .000), IgG3 (p = .000), and IgG4 (p = .029) was observed in MG patients. When the MG patients were divided into different groups, higher levels of IgG1 and IgG3 were observed in anti-AChR antibody positive group. Also, the level of IgG1 was statistically higher in female than that in male, and the level of IgG4 in late-onset group was significantly higher than that in early-onset group. There was a significant inverse correlation between the concentrations of IgG2 and IgG4 and disease duration. Our data suggested that IgG subclasses were preferentially produced during the process of MG, which could enable us a better understanding of MG.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.